Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 11 04:00PM ET
1.04
Dollar change
-0.12
Percentage change
-10.73
%
Index- P/E- EPS (ttm)-4.37 Insider Own52.88% Shs Outstand21.89M Perf Week-20.61%
Market Cap26.80M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float12.14M Perf Month-27.27%
Income-74.00M PEG- EPS next Q- Inst Own9.35% Short Float4.50% Perf Quarter-17.46%
Sales0.00M P/S- EPS this Y- Inst Trans12.77% Short Ratio0.36 Perf Half Y-62.59%
Book/sh-2.00 P/B- EPS next Y- ROA-73.13% Short Interest0.55M Perf Year-89.99%
Cash/sh0.01 P/C95.72 EPS next 5Y- ROE-118.66% 52W Range0.78 - 12.88 Perf YTD-62.18%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-91.93% Beta0.57
Dividend TTM- Quick Ratio0.04 Sales past 5Y-50.00% Gross Margin- 52W Low33.30% ATR (14)0.12
Dividend Ex-Date- Current Ratio0.04 EPS Y/Y TTM-3303.01% Oper. Margin0.00% RSI (14)35.64 Volatility8.63% 7.99%
Employees63 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-1486.44% Payout- Rel Volume0.23 Prev Close1.16
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume1.50M Price1.04
SMA20-17.67% SMA50-24.08% SMA200-55.43% Trades Volume340,501 Change-10.73%
Jun-12-24 01:05PM
Jun-03-24 08:05AM
May-23-24 05:05PM
May-21-24 09:53AM
May-20-24 11:41AM
08:05AM Loading…
08:05AM
May-16-24 08:05AM
Apr-29-24 08:00AM
Apr-25-24 04:05PM
Apr-24-24 04:45PM
Apr-18-24 04:05PM
Apr-16-24 11:53PM
Apr-11-24 08:05AM
Mar-25-24 04:05PM
Mar-06-24 07:52AM
08:00AM Loading…
Mar-04-24 08:00AM
Feb-07-24 08:57AM
Dec-29-23 07:30AM
Dec-28-23 04:05PM
Dec-27-23 08:00AM
Nov-14-23 04:48PM
Oct-26-23 08:00AM
Oct-24-23 10:53AM
08:00AM
Oct-19-23 08:00AM
Oct-17-23 08:00AM
Oct-11-23 08:00AM
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company was founded by Sangwoo Park in 2017 and is headquartered in Santa Ana, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Song Paul Y.Chief Executive OfficerDec 07 '23Buy3.2976250171,121Dec 07 05:23 PM
Song Paul Y.Chief Executive OfficerDec 06 '23Buy3.3275250171,045Dec 07 05:23 PM
Song Paul Y.Chief Executive OfficerDec 05 '23Buy3.33105350170,969Dec 05 03:51 PM
Graf James AInterim CFODec 04 '23Buy3.194501,436693Dec 05 03:50 PM
Song Paul Y.Chief Executive OfficerDec 04 '23Buy3.07163500170,864Dec 05 03:51 PM
Graf James AInterim CFODec 01 '23Buy3.35220737243Dec 05 03:50 PM
Song Paul Y.Chief Executive OfficerNov 27 '23Buy2.88244701170,701Nov 28 04:10 PM
Song Paul Y.Chief Executive OfficerNov 22 '23Buy2.8553150170,458Nov 22 05:53 PM
Song Paul Y.Chief Executive OfficerNov 21 '23Buy2.80100280170,405Nov 22 05:53 PM
Graf James AInterim CFONov 21 '23Buy2.92133823Nov 22 05:55 PM
Graf James AInterim CFONov 20 '23Buy2.94102910Nov 22 05:55 PM